Personalized medicine in multiple sclerosis: hope or reality?

被引：30

作者：

Derfuss, Tobias ^{[1
,2
]}

机构：

[1] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland

[2] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland

来源：

BMC MEDICINE | 2012年 / 10卷

关键词：

biomarker; multiple sclerosis; personalized medicine; LONG-TERM DISABILITY; NATURAL-HISTORY; INTERFERON-BETA; NEUTRALIZING ANTIBODIES; DEMYELINATING DISEASES; GENETIC RISK; FOLLOW-UP; THERAPY; COHORT; MULTICENTER;

D O I：

10.1186/1741-7015-10-116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is used to classify active and non-active patients and treatment responders and non-responders. Although this classification works on a group level, individual patients often behave differently from the group. Therefore additional biomarkers are needed to provide better indicators for prognosis and treatment response. Basic and clinical research have discovered different promising targets. It is now essential to verify the utility and accuracy of these markers in large, prospectively sampled patient cohorts.

引用

页数：5

共 35 条

[1]

[Anonymous], 2009, PHYS WORLD, V22, P21

[2] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study [J].

Arnason, BGW ;

Jacobs, G ;

Hanlon, M ;

Clay, BH ;

Noronha, ABC ;

Auty, A ;

Davis, B ;

Nath, A ;

Bouchard, JP ;

Belanger, C ;

Gosselin, F ;

Thibault, M ;

Duquette, P ;

Bourgoin, P ;

DuBois, R ;

Girard, M ;

Ebers, GC ;

Rice, GPA ;

Vandervoort, MK ;

Francis, GS ;

Duncan, L ;

Lapierre, Y ;

Freedman, MS ;

Christie, SN ;

Rabinovitch, HE ;

Patry, D ;

Murphy, WF ;

Peters, S ;

McGuiness, SD ;

Murray, TJ ;

Bhan, V ;

Maxner, CE ;

Van Dorpe, R ;

Oger, JJ ;

Nelson, J ;

Morrison, W ;

Bogle, N ;

Beall, S ;

Vorobeychick, G ;

Hiltbrunner, AV ;

Bock, J ;

Habil ;

Lesslauer, W ;

Li, DKB ;

Paty, DW ;

Zhao, GJ .

NEUROLOGY, 1999, 53 (03) :457-465

[3] MRI in multiple sclerosis: current status and future prospects [J].

Bakshi, Rohit ;

Thompson, Alan J. ;

Rocca, Maria A. ;

Pelletier, Daniel ;

Dousset, Vincent ;

Barkhof, Frederik ;

Inglese, Matilde ;

Guttmann, Charles R. G. ;

Horsfield, Mark A. ;

Filippi, Massimo .

LANCET NEUROLOGY, 2008, 7 (07) :615-625

[4] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[5] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].

Bloomgren, Gary ;

Richman, Sandra ;

Hotermans, Christophe ;

Subramanyam, Meena ;

Goelz, Susan ;

Natarajan, Amy ;

Lee, Sophia ;

Plavina, Tatiana ;

Scanlon, James V. ;

Sandrock, Alfred ;

Bozic, Carmen .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880

[6] Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan [J].

Chen, Pei ;

Lin, Juei-Jueng ;

Lu, Chin-Song ;

Ong, Cheung-Ter ;

Hsieh, Peiyuan F. ;

Yang, Chih-Chao ;

Tai, Chih-Ta ;

Wu, Shey-Lin ;

Lu, Cheng-Hsien ;

Hsu, Yung-Chu ;

Yu, Hsiang-Yu ;

Ro, Long-Sun ;

Lu, Chung-Ta ;

Chu, Chun-Che ;

Tsai, Jing-Jane ;

Su, Yu-Hsiang ;

Lan, Sheng-Hsing ;

Sung, Sheng-Feng ;

Lin, Shu-Yi ;

Chuang, Hui-Ping ;

Huang, Li-Chen ;

Chen, Ying-Ju ;

Tsai, Pei-Joung ;

Liao, Hung-Ting ;

Lin, Yu-Hsuan ;

Chen, Chien-Hsiun ;

Chung, Wen-Hung ;

Hung, Shuen-Iu ;

Wu, Jer-Yuarn ;

Chang, Chi-Feng ;

Chen, Luke ;

Chen, Yuan-Tsong ;

Shen, Chen-Yang .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) :1126-1133

[7] A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis [J].

Comabella, M. ;

Luenemann, J. D. ;

Rio, J. ;

Sanchez, A. ;

Lopez, C. ;

Julia, E. ;

Fernandez, M. ;

Nonell, L. ;

Camina-Tato, M. ;

Deisenhammer, F. ;

Caballero, E. ;

Tortola, M. T. ;

Prinz, M. ;

Montalban, X. ;

Martin, R. .

BRAIN, 2009, 132 :3353-3365

[8] Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine [J].

Comabella, Manuel ;

Vandenbroeck, Koen .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (05) :484-491

[9] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process [J].

Confavreux, C ;

Vukusic, S ;

Adeleine, P .

BRAIN, 2003, 126 :770-782

[10] Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort [J].

Cossburn, M. ;

Pace, A. A. ;

Jones, J. ;

Ali, R. ;

Ingram, G. ;

Baker, K. ;

Hirst, C. ;

Zajicek, J. ;

Scolding, N. ;

Boggild, M. ;

Pickersgill, T. ;

Ben-Shlomo, Y. ;

Coles, A. ;

Robertson, N. P. .

NEUROLOGY, 2011, 77 (06) :573-579

← 1 2 3 4 →